Consequently, CCR5 has been recognized as a key drug target against HIV (44), and here we discovered that infection of whole-blood samples with MVA downregulates cell surface expression of CCR5 in DCs, CD4+ T cells, CD8+ T cells, and B cells of HIV-1-infected patients. This evidence concerns the gene CD4 and infection.